{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-035040","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.141138+00:00","generated_at":"2026-05-30T00:37:36.117262+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Allarity Therapeutics reports Q3 net loss $12.2M; cash $18.5M; Phase 2 stenoparib patients exceed one year on treatment","bullets":["Net loss $12.2M vs $5.6M YoY; includes $9.7M non-cash intangible impairment charge.","Cash and equivalents $18.5M at Sept 30, 2024, up from $0.2M at Dec 31, 2023; runway into 2026.","Phase 2 stenoparib trial: two ovarian cancer patients exceeded one year on treatment.","Appointed Alexander Epshinsky as CFO; Jeremy Graff as President/Chief Development Officer; Jose Iglesias as Consultant CMO.","Regained NASDAQ compliance; European patent granted for stenoparib DRP companion diagnostic."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-035040","json":"https://secwatch.observer/filing/0001437749-24-035040.json","markdown":"https://secwatch.observer/filing/0001437749-24-035040.md","text":"https://secwatch.observer/filing/0001437749-24-035040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000143774924035040/0001437749-24-035040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000143774924035040/allr20241010c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:37:36.117262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}